11 March 2026Leadership
Fidelion appoints Dr Muthu Meyyappan as Chief Commercial Officer
Commercial, clinical-laboratory and regional market experience for Fidelion’s next phase.
Newsroom
Follow a company in motion
as its future comes into view
Follow Fidelion as we prepare VitaGuard for new markets and build a more continuous future for cancer follow-up.
Latest
The next chapter
is already being written
Company news, partnerships and milestones from the work behind VitaGuard.
Read the announcement →
28 January 2026Development
BGLC announces a phased regional deployment programme for VitaGuard
A staged programme for regional validation, operating readiness and responsible deployment.
1 December 2025Partnership
Exclusive Southeast Asia licence for VitaGuard technology executed
A regional foundation for technology transfer, validation and future access across Southeast Asia.
12 November 2025Company
BGLC enters definitive arrangement relating to Fidelion
The corporate and commercial framework around Fidelion and the VitaGuard opportunity takes shape.
Media resources
Fidelion at a glance
Company Fidelion Diagnostics Pte. Ltd., a private company incorporated in Singapore (UEN 202527265W).
Product VitaGuard™, a tumour-naive laboratory-developed ctDNA testing workflow with commercial operating experience. International rights outside Greater China have been assigned to Fidelion; new-market implementation remains subject to validation and applicable requirements.
Media enquiries media@fideliondx.com
This dated archive links to announcements filed by BioNexus Gene Lab Corp, a separate public company, and those filings may contain forward-looking statements. Website summaries do not replace the complete filings. VitaGuard remains subject to laboratory implementation, market-specific validation and applicable requirements in new markets.